← Human Trials & Peer-Reviewed Studies
A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation
Plain-language guide to PMID 19167733 (2009): double-blind randomized controlled trial study of Leuprolide and Goserelin in 159 patients.
Key Facts
- PMID
- 19167733
- Journal
- The Journal of urology
- Year
- 2009
- Study type
- Randomized Controlled Trial
- Authors
- Figg WD et al. (13 authors)
- DOI
- 10.1016/j.juro.2008.11.026
- Registered trial
- NCT00004635
What This Study Did, in Plain Language
What Was Tested
Researchers studied Leuprolide and Goserelin in this randomized controlled trial publication.
The researchers determined whether thalidomide can prolong progression-free survival in men with biochemically recurrent prostate cancer treated with limited androgen deprivation therapy.
Who Took Part
The abstract describes 159 patients taking part.
By PubMed's age tags, the people studied were middle-aged adults, older adults and people over 80, men only.
Patients were then crossed over to the opposite drug and were treated until prostate specific antigen progression (oral phase B).
How the Study Was Run
In design terms this was a randomized, double-blind, placebo-controlled and crossover study.
Random assignment meant chance, not the researchers, decided who got Leuprolide and who got the comparison, which limits bias.
Blinding on both sides kept the patients and researchers unaware of who received Leuprolide.
The comparison arm used a placebo, so changes seen with Leuprolide could be set against what happens without it.
Each person switched between Leuprolide and the comparison at some point, usually with a gap in between.
At the time of prostate specific antigen progression gonadotropin-releasing hormone agonist was restarted for 6 additional months.
Testosterone and dihydroxytestosterone were likewise monitored throughout the study.
What Was Measured
PubMed files the paper under topics including Androgens, Angiogenesis Inhibitors, Antineoplastic Agents, Hormonal, Goserelin, Leuprolide, Prostatic Neoplasms and Thalidomide.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Leuprolide and Goserelin in 159 patients.
Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2009 (The Journal of urology), a journal based in United States.
More context: the Leuprolide compound page and the Goserelin compound page.
Our Notes on the Compounds
Leuprolide: A 9-amino-acid GnRH analog (Lupron, Eligard) that lowers sex-hormone levels with ongoing use; used in prostate cancer, endometriosis and early puberty.
Goserelin: A GnRH analog implant (Zoladex) used to lower sex-hormone levels in prostate and breast cancer and gynecologic conditions.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.